HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket

Tissue Antigens

Volumn 49, Issue 6, 1997, Pages 580-587

  Garcia F ^a   Galocha, B ^a   Villadangos, J A ^a   Lamas, J R ^a   Albar, J P ^b   Marina, A ^a   Lopez De Castro J A ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Ankylosing spondylitis; HA B27; Peptide motif

Indexed keywords

ARGININE; GLUTAMINE; HLA B27 ANTIGEN; LEUCINE;

ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; DNA POLYMORPHISM; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0030996059     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1997.tb02805.x     Document Type: Article

References (44)

1. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973: 1: 904-7.
2. Kingsley G, Sieper J. Current perspectives in reactive arthritis. Immunol Today 1993: 14: 387-91.
3. Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990: 11: 137-42.
4. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 1993: 150: 4168-78.
5. Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med 1993: 178: 1607-16.
6. Breban M, Fernandez-Sueiro JL, Richardson JA, Hadavand RR, Maika SD, Hammer RE, Taurog JD. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996: 156: 794-803.
7. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993: 342: 646 50.
8. Breur-Vriesendorp BS, Dekker Saeys AJ, Ivanyi P. Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules. Ann Rheum Dis 1987: 46: 353-6.
9. Lopez-Larrea C, Sujirachato K, Mehra NK et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens 1995: 45: 169-76.
10. D'Amato M, Fiorillo MT, Carcassi C et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995: 25: 3199-201.
11. Nasution AR, Mardjuadi A, Kunmartini S et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol (in press).
12. López de Castro JA. Structural polymorphism and function of HLA-B27. Curr Opin Rheumatol 1995: 7: 270-8.
13. Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995: 7: 263-9.
14. Gonzalez-Roces S, Brautbar C, Pena M et al. Molecular analysis of HLA-B27 haplotypes in Caucasoids. Frequencies of B27-Cw in Jewish and Spanish populations. Hum Immunol 1994: 41: 127-34.
15. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992: 70: 1035-48.
16. Rotzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 1994: 39: 74-7.
17. Fruci D, Butler RH, Greco G et al. Differences in peptide-binding specificity of two ankylosing spondylitis-associated HLA-B27 subtypes. Immunogenetics 1995: 42: 123-8.
18. Choo SY, Antonelli P, Nisperos B, Nepom GT, Hansen JA. Six variants of HLA-B27 identified by isoelectric focusing. Immunogenetics 1986: 23: 24-9.
19. Parham P, Adams EJ, Arnett KL. The origins of HLA-A,B,C polymorphism. Immunol Rev 1995: 143: 141-80.
20. Tanigaki N, Fruci D, Vigneti E et al. The peptide binding specificity of HLA-B27 subtypes. Immunogenetics 1994: 40: 192-8.
21. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991: 353: 326-9.
22. Villadangos JA, Galocha B, Garcia F, Albar JP, López de Castro JA. Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703. Eur J Immunol 1995: 25: 2370-7.
23. Calvo V, Rojo S, Lopez D, Galocha B, López de Castro JA. Structure and diversity of HLA-B27-specific T cell epitopes. Analysis with site-directed mutants mimicking HLA-B27 subtype polymorphism. J Immunol 1990: 144: 4038-45.
24. Villadangos JA, Galocha B, López de Castro JA. Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity. J Immunol 1994: 152: 2317-23.
25. Benjamin RJ, Madrigal JA, Parham P. Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 1991: 351: 74-7.
26. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985: 162: 1745-59.
27. Townsend A, Ohlen C, Bastin J, Ljunggren HG, Foster L, Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989: 340: 443-8.
28. Ljunggren HG, Stam NJ, Ohlen C et al. Empty MHC class I molecules come out in the cold. Nature 1990: 346: 476-80.
29. Ellis SA, Taylor C, McMichael A. Recognition of HLA-B27 and related antigens by a monoclonal antibody. Hum Immunol 1982: 5: 49-59.
30. Brodsky FM, Bodmer WF, Parham P. Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur J Immunol 1979: 9: 536-45.
31. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes. HLA and other human cell surface antigens. New tools for genetic analysis. Cell 1978: 14: 9-20.
32. Galocha B, Lamas JR, Villadangos JA, Albar JP, López de Castro JA. Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Tissue Antigens 1996: 48: 509-18.
33. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991: 351: 290-6.
34. Parker KC, Biddison WE, Coligan JE. Pocket mutations of HLA-B27 show that anchor residues act cumulatively to stabilize peptide binding. Biochemistry 1994: 33: 7736-43.
35. Rojo S, Garcia F, Villadangos JA, López de Castro JA. Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B. J Exp Med 1993: 177: 613-20.
36. Smith KJ, Reid SW, Stuart DI, McMichael AJ, Jones EY, Bell JI. An altered position of the α2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Immunity 1996: 4: 203-13.
37. Raghavan M, Lebron J, Johnson J, Bjorkman P. Extended repertoire of permissible peptide ligands for HLA-B*2702. Protein Sci 1996: 5: 2080-8.
38. López de Castro JA. HLA-B27 and HLA-A2 subtypes: structure, evolution and function. Immunol Today 1989: 10: 239-46.
39. Garcia F, Marina A, López de Castro JA. Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated with ankylosing spondylitis. Tissue Antigens 1997: 49: 215-21.
40. Fiorillo MT, Meadows L, D'Amato M, Shabanowitz J, Hunt DF, Apella E, Sorrentino R. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 1997: 27: 368-373.
41. MacLean L. HLA-B27 subtypes: implications for the spondyloarthropathies. Ann Rheum Dis 1992: 51: 929-31.
42. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995: 41: 178-228.
43. Garcia F, Marina A, Albar JP, López de Castro JA. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. Tissue Antigens 1997: 49: 23-8.
44. Boisgérault F, Tieng V, Stolzenberg MC, Dulphy N, Khalil I, Tamouza R, Charron D, Toubert A. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants: implications for susceptibility to spondylarthropathies. J Clin Invest 1996: 98: 2764-2770.